Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 16K citations

Pharmacy, Oncology, Cancer Symptom Management +15

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine · 2004 · 5.7K citations

Medicine, Oncology, Urology +12

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain et al. · New England Journal of Medicine · 2004 · 3.7K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

Willi Kreis, Daniel R. Budman, James Fetten et al. · Annals of Oncology · 1999 · 157 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.

David Friedland, Jonathan E. Cohen, Rachel Miller et al. · PubMed · 1999 · 155 citations

Medicine, Oncology, Pharmacology +12